- An analyst from Truist Financial recently lowered their price target for Insmed to $185.00, suggesting a significant potential upside of 58.72% from its trading price of $116.56.
- Despite a 23% stock drop following its first-quarter 2026 results, Insmed reported substantial quarterly revenues of $305.96 million, though it narrowly missed the consensus estimate.
- Insmed’s earnings performance surpassed expectations, posting an improved loss of $0.76 per share compared to the anticipated loss of $0.90 per share.
Insmed (NASDAQ: INSM) is a leading biopharmaceutical company focused on developing innovative treatments for serious and rare diseases. A recent stock analysis from Truist Financial saw their price target for Insmed adjusted to $185.00. At the time of this rating, the biotech stock was trading at $116.56, indicating a significant potential upside of 58.72% to the new target.
This analyst’s positive outlook comes even as Insmed’s stock dropped 23% after its first-quarter 2026 results, as highlighted by Zacks. The company announced quarterly revenues of $305.96 million. While this is a substantial increase from the $92.82 million reported a year ago, it narrowly missed the consensus estimate of $308.10 million.
Despite the revenue miss, Insmed’s earnings performance was better than expected. The company posted a loss of $0.76 per share, which was an improvement over the anticipated loss of $0.90 per share. Earnings per share (EPS) is a key measure of a company’s profit allocated to each outstanding share of stock.
The company’s new lung drug, Brinsupri, showed strong performance with $207.90 million in sales, driven by robust patient demand. As noted by Investors.com, the drug’s launch missed some high expectations, which contributed to the stock’s decline. Looking ahead, Insmed expects Brinsupri sales to reach at least $1.00 billion and reaffirmed its 2026 guidance for its other drug, Arikayce.
